These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25758153)

  • 1. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
    Halim AB
    Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biggest challenges currently facing companion diagnostic advancement.
    Halim AB
    Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving laboratory efficiencies through significant time reduction in the preanalytical phase.
    Prusa R; Doupovcova J; Warunek D; Stankovic AK
    Clin Chem Lab Med; 2010 Feb; 48(2):293-6. PubMed ID: 20001850
    [No Abstract]   [Full Text] [Related]  

  • 5. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
    Love D; Stratton E; Stocum M
    N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming regulatory and economic challenges facing pharmacogenomics.
    Cohen JP
    N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Regulation of Companion Diagnostics: A Global Perspective.
    Ansari M
    Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory considerations for companion diagnostic devices.
    Lee EY; Shen HC
    Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
    Scheen AJ
    Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualification versus validation of biomarkers.
    Doust J
    Scand J Clin Lab Invest Suppl; 2010; 242():40-3. PubMed ID: 20515275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preanalytical quality improvement: from dream to reality.
    Lippi G; Chance JJ; Church S; Dazzi P; Fontana R; Giavarina D; Grankvist K; Huisman W; Kouri T; Palicka V; Plebani M; Puro V; Salvagno GL; Sandberg S; Sikaris K; Watson I; Stankovic AK; Simundic AM
    Clin Chem Lab Med; 2011 Jul; 49(7):1113-26. PubMed ID: 21517699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of genetic biomarkers on drug and companion diagnostic return on investment.
    Keeling P
    Drug Discov Today; 2011 Oct; 16(19-20):850-1. PubMed ID: 21906694
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
    Miossec P; Verweij CL; Klareskog L; Pitzalis C; Barton A; Lekkerkerker F; Reiter S; Laslop A; Breedveld F; Abadie E; Flamion B; Dere W; Mpofu S; Goel N; Ethgen D; Mitlak B; Ormarsdóttir S; Rao R; Tsouderos Y; Reginster JY;
    Ann Rheum Dis; 2011 Oct; 70(10):1713-8. PubMed ID: 21784723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.